Drug Trial Radar · NCT02475317
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
Last checked: Nov 19, 2026Latest source record: Apr 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jun 1, 2015
Primary completion
Dec 1, 2015
Study completion Dec 1, 2015
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same.
Conditions
- Healthy Volunteers
Interventions
PlaceboDrug
Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
MaralixibatDrug
Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
VolixibatDrug
Participants will receive volixibat in 10 mg and 20 mg doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of Fecal Bile Acid Excretion After Dosing (Day 6 and Day 7)Time frame: Baseline, Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Orleans Center for Clinical Research
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.